PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-8.53%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
0.41%
Positive gross profit growth while META is negative. John Neff would see a clear operational edge over the competitor.
4.92%
Positive EBIT growth while META is negative. John Neff might see a substantial edge in operational management.
4.92%
Positive operating income growth while META is negative. John Neff might view this as a competitive edge in operations.
2.25%
Net income growth under 50% of META's 22.88%. Michael Burry would suspect the firm is falling well behind a key competitor.
4.00%
EPS growth under 50% of META's 19.05%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
No Data
No Data available this quarter, please select a different quarter.
0.44%
Share reduction more than 1.5x META's 2.10%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.47%
Diluted share reduction more than 1.5x META's 1.99%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-16.17%
Negative OCF growth while META is at 4.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.41%
Negative FCF growth while META is at 23.26%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
2318.93%
10Y revenue/share CAGR above 1.5x META's 223.71%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
162.39%
5Y revenue/share CAGR at 50-75% of META's 223.71%. Martin Whitman would worry about a lagging mid-term growth trajectory.
71.93%
3Y revenue/share CAGR under 50% of META's 223.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
2057.92%
10Y OCF/share CAGR above 1.5x META's 252.27%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
82.98%
Below 50% of META's 252.27%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
32.35%
3Y OCF/share CAGR under 50% of META's 252.27%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
5415.81%
Net income/share CAGR above 1.5x META's 159.38% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
127.41%
5Y net income/share CAGR at 75-90% of META's 159.38%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
83.56%
3Y net income/share CAGR 50-75% of META's 159.38%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
12534.36%
Equity/share CAGR of 12534.36% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
188.03%
Equity/share CAGR of 188.03% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
79.49%
Equity/share CAGR of 79.49% while META is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.88%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-20.89%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.05%
Asset growth at 75-90% of META's 6.33%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
4.59%
75-90% of META's 5.96%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
19.03%
We have some new debt while META reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
0.71%
R&D dropping or stable vs. META's 11.52%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.99%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.